Adenine-Induced CKD Model: Practical Guide to Renal Fibrosis
A deep dive into the adenine-induced CKD model for renal fibrosis. Tubulointerstitial nephritis mechanism, UUO differences, and BUN/Creatinine tips.
The Adenine-Induced CKD Model: A Non-Surgical Pathway to Renal Failure
Choosing the appropriate animal model in the preclinical stage is paramount for drug discovery targeting Chronic Kidney Disease (CKD). Globally, the most recognized model for renal fibrosis is the Unilateral Ureteral Obstruction (UUO) model. However, because UUO induces rapid, irreversible hydronephrosis and fibrosis via an acute surgical insult, it often diverges significantly from the "chronic" functional decline observed in human CKD progressively driven by metabolic or toxic factors.
A robust and highly translational alternative to address this limitation is the Adenine-induced CKD model. In this article, we explain the pathological mechanisms of this non-invasive, diet-induced model, its crucial advantages over the UUO model, and practical know-how for ensuring a successful study design.
1. Mechanism of Adenine Induction: How Does It Destroy the Kidneys?
When adenine (a purine base) is consumed in vast excess, the purine metabolism pathway in mammals becomes completely saturated.
- Conversion to 2,8-DHA: The unmetabolized excess adenine is oxidized by the enzyme xanthine dehydrogenase into 2,8-dihydroxyadenine (2,8-DHA), a highly insoluble metabolite.
- Crystallization in Renal Tubules: As the kidney attempts to excrete 2,8-DHA, the poor solubility causes it to precipitate and form countless crystals within the tubular lumen.
- The Inflammatory and Fibrotic Cascade: The physical obstruction caused by these crystals, combined with the direct cellular injury they inflict, triggers a massive infiltration of macrophages, leading to severe Tubulointerstitial Nephritis. If this persists, it drives a cascade resulting in irreversible interstitial fibrosis and ultimate renal failure.
This process closely mimics the mechanisms of uric acid nephropathy and certain drug-induced tubulointerstitial injuries in humans, providing excellent validity for modeling metabolic- and toxicity-driven renal pathologies.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Adenine Model vs. UUO Model: Which Should You Choose?
When outsourcing to a CRO or establishing an assay internally, should you opt for UUO or the Adenine model? We compare their characteristics to help you define your criteria.
| Feature | Adenine-Induced Model (Oral Gavage) | Adenine-Induced Model (Diet Admixture) | UUO Model (Surgical Ligation) |
|---|---|---|---|
| Induction Method | Oral gavage (Moderately invasive) | Dietary intake (Non-invasive) | Surgery (Invasive) |
| Dosing Accuracy | ⭕️ High (Independent of appetite) | ❌ Variable (Due to strong taste aversion in mice) | - |
| Speed of Fibrosis | Moderate (Typically 3-6 weeks) | Moderate to Slow (Typically 4-6 weeks) | Very Rapid (Typically 7-14 days) |
| Distribution of Lesions | Bilateral (Uniform across both kidneys) | Bilateral (Uniform across both kidneys) | Unilateral (Strictly ligated side) |
| Assessment of Renal Functional Decline | ⭕️ Possible (Elevated BUN & Creatinine) | ⭕️ Possible (Elevated BUN & Creatinine) | ❌ Difficult (Contralateral kidney compensates) |
| Primary Use Case | Highly consistent evaluation of functional endpoints | General evaluation of functional endpoints | Rapid screening of strong anti-fibrotic compound activity |
| Management Challenges | Requires daily handling, but yields low inter-animal variability | Requires strict monitoring of weight loss and variable intake | Requires minimizing variability in surgical technique |
The most critical differentiator is the ability to evaluate systemic renal dysfunction (blood parameters). While UUO is excellent for morphological evaluation of fibrosis, if your compound's value proposition requires demonstrating an improvement in BUN or serum creatinine, the bilateral systemic failure of the Adenine model becomes absolutely necessary.
3. Practical Protocol and Evaluation Strategies
Here are the standard protocols and crucial tips to lead your adenine model to success.
① The Difference Between Rat and Mouse Models
The adenine-induced CKD model is well-established in both rats and mice, but they exhibit distinct responsiveness:
- Rats: Rats generally have a robust and highly sensitive response to adenine. They reliably develop consistent renal impairment and prominent cardiovascular comorbidities like "vascular calcification" characteristic of severe CKD. Historically, there is a massive wealth of data using the rat adenine model.
- Mice: Mice exhibit significant strain-dependent susceptibility. Commonly used strains like C57BL/6 are prone to severe weight loss and higher mortality rates compared to rats. Therefore, precise dose titration and the use of "washout protocols" (described below) are far more critical when modeling in mice.
② Route of Administration: Diet Admixture vs. Oral Gavage
There are two primary approaches to administering adenine to the animals, each with distinct trade-offs:
- Diet Admixture: Providing a custom diet containing adenine (e.g., 0.2% to 0.25% or 0.75%) ad libitum. This method avoids daily handling stress and is highly scalable. However, mice exhibit a distinct taste and smell aversion to adenine, typically leading to a significant reduction in food intake (a problem less prominent in rats, which is why rat models have historically relied on this method). This aversion leads to inconsistent adenine consumption and increased intra-group variability in mice.
- Oral Gavage: Administering a suspension of adenine (e.g., in 0.5% CMC) directly via oral gavage daily. This method has been increasingly favored in recent publications. While it introduces handling stress, it guarantees that exact dosages (e.g., 50 mg/kg/day) are delivered to every individual precisely, regardless of their appetite, thereby drastically minimizing variability in fibrosis and functional readouts.
③ Duration, Dosing, and the "Washout" Technique
Typically, adenine is administered continuously for 3 to 6 weeks. Distinct tubulointerstitial inflammation and early fibrosis are reliably observable by weeks 3 to 4.
Particularly in mice, continuous adenine administration and the associated taste aversion can lead to drastic weight loss and unacceptably high mortality rates. To circumvent this, many validated CRO protocols employ the following clever modification:
- Administer Adenine for 2 to 3 weeks → Switch back to a normal state (standard chow / vehicle gavage) for a 2-4 week observation/dosing window. Even after suspending adenine intake, the inflammatory and fibrotic cascades triggered by the initial crystal deposition progress autonomously. Using this "washout" or "pulsed" protocol allows researchers to maintain high survival rates while securing a clean evaluation period free from the acute toxicity of ongoing adenine ingestion.
③ Key Endpoints for Evaluation
- Blood Biochemistry: Assessment of renal clearance function via Blood Urea Nitrogen (BUN), serum creatinine, and serum phosphorus.
- Histopathological Evaluation:
- Sirius Red or Masson's Trichrome Staining: Quantification of the interstitial collagen deposition area.
- Immunohistochemistry (IHC): Quantification of markers such as α-SMA (activated myofibroblasts), F4/80 or CD68 (macrophage infiltration), and Col1a1.
- Biomarkers: Measurement of urinary NGAL (acute kidney injury marker) or urinary albumin excretion (albuminuria).
4. The Strategic Value of the Adenine Model in CKD Drug Discovery
In the preclinical evaluation of highly sought-after mechanisms—such as SGLT2 inhibitors (e.g., Dapagliflozin), non-steroidal mineralocorticoid receptor antagonists (e.g., Finerenone), and the emerging GLP-1 receptor agonists—there is a strict requirement to prove not just a "better fibrosis score," but actual improvement in metabolic/functional indices like glomerular filtration.
The Adenine-induced CKD model provides a highly translational platform capable of simultaneously evaluating both these functional endpoints and histological anti-fibrotic efficacy.
Our partnered preclinical CRO network provides access to strictly controlled Adenine models (in both mice and rats) with established survival/washout protocols, alongside traditional UUO models. We can assist you from the initial study design phase (Prophylactic vs. Therapeutic), so please feel free to reach out to us.